Elagolix

🧮 Dose calculator

Endometriosis · Regimen source: FDA Orilissa · 2.1, Table 1

• • Exclude pregnancy or start within 7 days of menses. Moderate hepatic impairment: 150 mg only, max 6 months. FDA Orilissa · 2.1FDA Orilissa · 2.2

Enter age (weight is optional for this regimen).

👥 Special populations

• 🤰 PregnancyContraindicated

  Label: contraindicated in pregnancy. FDA Orilissa · 4

  “ORILISSA is contraindicated in women: Who are pregnant [see Use in Specific Populations ( 8.1 )] .”

• 🤱 BreastfeedingUse with caution

  Label: use with caution while breastfeeding; see the label text. FDA Orilissa · 8.2

  “Risk Summary There is no information on the presence of elagolix or its metabolites in human milk, the effects on the breastfed child, or the effects on milk production.”

• 👶 ChildrenSafety not established

  Label: safety and effectiveness in children have not been established. FDA Orilissa · 8.4

  “Safety and effectiveness of ORILISSA in pediatric patients have not been established.”

• 👴 Older adultsNo data

  The source for this drug has no section for this group.

• ⚥ Females & males of reproductive potentialUse with caution

  Label has advice on pregnancy testing, contraception or fertility for females and males. FDA Orilissa · 8.3

  “Contraception Advise women to use effective non-hormonal contraception during treatment with ORILISSA and for 28 days after discontinuing ORILISSA [see Warnings and Precautions ( 5.5 )] .”